HER-2 positive	Salivary Gland Cancer	HER-2 positive	Salivary Gland Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
PD-L1 expression	Salivary Gland Cancer	PD-L1 expression	Salivary Gland Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Salivary Gland Cancer	No biomarker	Salivary Gland Cancer	cisplatin + doxorubicin hydrochloride + cyclophosphamide Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + cyclophosphamide Sensitive : A2	cisplatin + doxorubicin hydrochloride + cyclophosphamide Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + cyclophosphamide Sensitive : A2
No biomarker	Salivary Gland Cancer	No biomarker	Salivary Gland Cancer	cisplatin + vinorelbine tartrate Sensitive: A2 - Guideline cisplatin + vinorelbine tartrate Sensitive : A2	cisplatin + vinorelbine tartrate Sensitive: A2 - Guideline cisplatin + vinorelbine tartrate Sensitive : A2
NTRK2 fusion	Salivary Gland Cancer	NTRK2 fusion	Salivary Gland Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Salivary Gland Cancer	NTRK1 fusion	Salivary Gland Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Salivary Gland Cancer	NTRK3 fusion	Salivary Gland Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Salivary Gland Cancer	NTRK3 fusion	Salivary Gland Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Salivary Gland Cancer	NTRK1 fusion	Salivary Gland Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Salivary Gland Cancer	NTRK2 fusion	Salivary Gland Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2	leuprolide acetate Sensitive: A2 - Guideline leuprolide acetate Sensitive : A2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2	bicalutamide Sensitive: A2 - Guideline bicalutamide Sensitive : A2
RET fusion	Salivary Gland Cancer	RET fusion	Salivary Gland Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
HER-2 positive	Salivary Gland Cancer	HER-2 positive	Salivary Gland Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2	fam-trastuzumab deruxtecan-nxki Sensitive: A2 - Guideline fam-trastuzumab deruxtecan-nxki Sensitive : A2
No biomarker	Salivary Gland Cancer	No biomarker	Salivary Gland Cancer	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2
No biomarker	Salivary Gland Cancer	No biomarker	Salivary Gland Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Salivary Gland Cancer	No biomarker	Salivary Gland Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
BRAF V600E	Salivary Gland Cancer	BRAF V600E	Salivary Gland Cancer	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2	trametinib + dabrafenib Sensitive: A2 - Guideline trametinib + dabrafenib Sensitive : A2
HER-2 overexpression	Salivary Gland Cancer	HER-2 overexpression	Salivary Gland Cancer	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1	trastuzumab Sensitive: C1 - Off-label trastuzumab Sensitive : C1
HER-2 expression	Salivary Gland Cancer	HER-2 expression	Salivary Gland Cancer	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1	fam-trastuzumab deruxtecan-nxki Sensitive: C1 - Off-label fam-trastuzumab deruxtecan-nxki Sensitive : C1
RET fusion	Salivary Gland Cancer	RET fusion	Salivary Gland Cancer	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1	pralsetinib Sensitive: C1 - Off-label pralsetinib Sensitive : C1
HER-2 positive	Salivary Gland Cancer	HER-2 positive	Salivary Gland Cancer	trastuzumab-pkrb Sensitive: C1 - Off-label trastuzumab-pkrb Sensitive : C1	trastuzumab-pkrb Sensitive: C1 - Off-label trastuzumab-pkrb Sensitive : C1
EGFR expression	Salivary Gland Cancer	EGFR expression	Salivary Gland Cancer	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1	cetuximab Sensitive: C1 - Off-label cetuximab Sensitive : C1
HER-2 amplification	Salivary Gland Cancer	HER-2 amplification	Salivary Gland Cancer	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2	trastuzumab + pertuzumab Sensitive: C2 – Inclusion Criteria trastuzumab + pertuzumab Sensitive : C2
HER-2 amplification	Salivary Gland Cancer	HER-2 amplification	Salivary Gland Cancer	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2	ado-trastuzumab emtansine Sensitive: C2 – Inclusion Criteria ado-trastuzumab emtansine Sensitive : C2
HER-2 overexpression	Salivary Gland Cancer	HER-2 overexpression	Salivary Gland Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2
HER-2 amplification	Salivary Gland Cancer	HER-2 amplification	Salivary Gland Cancer	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2	trastuzumab Sensitive: C2 – Inclusion Criteria trastuzumab Sensitive : C2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2	darolutamide Sensitive: C2 – Inclusion Criteria darolutamide Sensitive : C2
AR positive	Salivary Gland Cancer	AR positive	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3
PLIN2 expression	Salivary Gland Cancer	PLIN2 expression	Salivary Gland Cancer	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3	leuprolide acetate + bicalutamide Sensitive: C3 – Early Trials leuprolide acetate + bicalutamide Sensitive : C3
AKT1 E17K	Salivary Gland Cancer	AKT1 E17K	Salivary Gland Cancer	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3	capivasertib Sensitive: C3 – Early Trials capivasertib Sensitive : C3
HER-2 expression	Salivary Gland Cancer	HER-2 expression	Salivary Gland Cancer	JNJ-0683 Sensitive: C3 – Early Trials JNJ-0683 Sensitive : C3	JNJ-0683 Sensitive: C3 – Early Trials JNJ-0683 Sensitive : C3

Salivary Gland Cancer

Associations(57)

Associations
(57)